S926
Clinical - Mixed sites & palliation
ESTRO 2026
Médico de Oncología Avanzada, Madrid, Spain. 5 Medical Director, Radiation Oncology, INMOA - Instituto Médico de Oncología Avanzada, Madrid, Spain
Conclusion: Lattice SBRT provides rapid and promising tumor response with minimal toxicities in patients with advanced, refractory diseases, fair performance statuses, and/or limited treatment alternatives. Future multi-center, prospective, validation studies are warranted to standardize treatment algorithms and optimize patient management. References: 1. Duriseti S, Kavanaugh J, Goddu S, et al. Spatially fractionated stereotactic body radiation therapy (Lattice) for large tumors. Adv Radiat Oncol. 2021 Jan 8;6(3):100639.2. Washington University School of Medicine: A Trial of Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients with Sarcoma, Thoracic, Abdominal, and Pelvic Cancers [Internet]. clinicaltrials.gov; 2023. [cited 2025 Nov 13] Available online: https://cdn.clinicaltrials.gov/large- docs/71/NCT04553471/Prot_SAP_000.pdf. Assessed on 10th November, 2025. Keywords: Lattice SBRT, SFRT, large tumor Digital Poster 4713 Real world quality-of-life outcomes after modulated electro-hyperthermia across tumour types. Claudia F. Pedrero 1 , Patricia Jaimes 2 , Lucrecia Ruiz 3 , Ariane Ruiz Novo 2 , Elsa Pérez Arroyo 4 , Elisabeth Arrojo 5 1 Radiation Oncology, INMOA - Instituto Médico de Oncología Avanzada, Madrid, Spain. 2 Clinical Department, INMOA - Instituto Médico de Oncología Avanzada, Madrid, Spain. 3 Medical Oncology, INMOA - Instituto Médico de Oncología Avanzada, Madrid, Spain. 4 Radiation Therapy Unit, INMOA - Instituto
Digital Poster 4751 Combining Deep Hyperthermia with Radiotherapy: Feasibility, Safety, and Clinical Outcomes in a Retrospective Patient Cohort. Francesco Martucci 1 , Lisa Milan 2 , Calin Simion Toma Micle 1 , Stefano Leva 1 , Antonio Angrisani 1 , Margherita Casiraghi 2 , Deborah Daniele 1 , Domenico Santoro 1 , Thomas Zilli 1,3 , Letizia Deantonio 1,3 1 Radiation Oncology Clinic, EOC, Bellinzona, Switzerland. 2 Medical Physics Division, EOC, Bellinzona, Switzerland. 3 Facoltà Di Scienze Biomediche, Università Della Svizzera Italiana (USI), Lugano, Switzerland Purpose/Objective: This retrospective study evaluates treatment tolerance and preliminary outcomes of combining deep hyperthermia (dHT) with radiotherapy (RT) in a cohort of patients with advanced or recurrent cancers. Material/Methods: Between 2022 and 2025, 57 patients (median age, 68 years; range, 40–87 years) received concomitant dHT and RT. The cohort included: 11 sarcomas (19%), 9 pelvic tumours (16%), 20 bone metastases (35%), and 17 lymph nodes, pancreas, or soft tissues (30%). ECOG performance status was 0-1 in 45 patients (79%) and 2–3 in 12 (21%). RT and dHT were palliative in 91% of cases, and 35% also received systemic therapy. The median RT dose was 39 Gy (range: 20–66 Gy), delivered in 5–33 fractions using VMAT. The gross tumour volume had a median of 93.1 cc (range, 8–
Made with FlippingBook - Share PDF online